Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Randomized, Dose-ranging Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers (TEJAS-2)

NCT06760702 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.

NCT NCT06760702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06760702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Randomized, Dose-ranging Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers (TEJAS-2)
Lead sponsor
Aurigene Discovery Technologies Limited
Phase
Phase 2
Overall status
Terminated
Start date
November 9, 2024
Completion date
February 1, 2026
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, ovarian cancer, renal cancer